Cardiol Therapeutics Inc.
NASDAQ:CRDL · NASDAQ Capital Market
-$0.01 today
Vol 0.26M · Avg 0.68M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-189.2%
avg -92.0%
ROIC
-190.6%
avg -92.2%
ROA
-143.2%
avg -75.6%
Analysis
ROA is currently the strongest return metric at -143.2% versus its period average of -75.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Andrew Warwick Hamer | Chief Medical Officer and Head of Research & Development | $572,892.00 | — | 64 | — | — |
David G. Elsley | President, Chief Executive Officer & Director | $553,409.00 | — | — | — | — |
Bernard Lim | Chief Operating Officer | $379,683.00 | — | — | — | — |
Christopher J. Waddick | Chief Financial Officer, Corporate Secretary & Director | $216,962.00 | — | — | — | — |
Trevor Burns | Investor Relations | — | — | — | — | — |
John A. Geddes BSCPT | Vice President of Corporate Development | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
No insider transactions in the last 12 months.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A0 analysts |
| Net Income | N/A | N/A | N/A | N/A0 analysts |
| EBIT | N/A | N/A | N/A | N/A0 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Assertio Holdings, Inc.
NASDAQ:ASRT
$151.86M
Hyperfine, Inc.
NASDAQ:HYPR
$133.06M
InflaRx N.V.
NASDAQ:IFRX
$130.74M
Connect Biopharma Holdings Limited
NASDAQ:CNTB
$125.61M
Kalaris Therapeutics Inc
NASDAQ:KLRS
$89.77M
Microbot Medical Inc.
NASDAQ:MBOT
$83.17M
Vivani Medical, Inc.
NASDAQ:VANI
$68.83M
ImageneBio Inc
NASDAQ:IMA
$67.71M
InterCure Ltd.
NASDAQ:INCR
$53.08M
InspireMD, Inc.
NSPR
$33.26M
Who manages CRDL?
Cardiol Therapeutics Inc. (CRDL) lists 6 active executives. The top listed executive is Andrew Warwick Hamer, Chief Medical Officer and Head of Research & Development.
Explore More
Continue the stock analysis
Jump to another research area for this company.